Motion Sickness
CB receptors line the inner-ear balance pathway — an intriguing target, but there is no human clinical evidence yet.
Other Emerging
What the research says
This one is all mechanism, no proof. Cannabinoid CB1 and CB2 receptors are present throughout the inner-ear and vestibular pathways, and animal work suggests endocannabinoid signaling participates in balance and in how the brain adapts to vestibular disturbance. A 2022 review in Frontiers in Pharmacology laid out the case that the system is a plausible therapeutic target for motion sickness and other vestibular disorders.
That is where the evidence stops. There are no randomized trials, no case series — nothing clinical — testing cannabis for motion sickness in humans. Antihistamines (dimenhydrinate, meclizine) and scopolamine remain the studied, effective options.
The honest caveats
Even the mechanism is hypothesis — and intoxication adds a second problem on top of the first (nausea plus impairment while driving or flying). If you are prone to motion sickness, use the evidence-based prevention: take the studied medications early, look at the horizon, and avoid heavy meals. Cannabis is an unexplored, unproven, and risky substitute.
Compounds to explore
These are the compounds — terpenes and cannabinoids — that the research connects to this condition. They are starting points for reading a COA or choosing a product, not prescriptions. Each has its own guide with more detail.
Cannabinoid CBD Anti-nausea mechanisms make it a speculative candidate — no motion-sickness data. Cannabinoid THC Classic anti-nausea compound, but intoxication and travel do not mix well. Terpene limonene Traditional 'settle the stomach' terpene; unproven for motion sickness.